RHBC
EW icon

R.H. Bluestein & Co’s Edwards Lifesciences EW Stock Holding History

R.H. Bluestein & Co’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$16.9M Buy
204,527
+880
+0.4% +$84.7K 1.05% 28
2022
Q2 		$19.4M Buy
203,647
+995
+0.5% +$103K 1.19% 24
2022
Q1 		$23.9M Sell
202,652
-4,652
-2% -$522K 1% 30
2021
Q4 		$26.9M Buy
207,304
+86,688
+72% +$10.1M 0.96% 39
2021
Q3 		$13.7M Buy
120,616
+90,742
+304% +$10.4M 0.54% 40
2021
Q2 		$3.09M Sell
29,874
-5,891
-16% -$555K 0.12% 58
2021
Q1 		$2.99M Buy
35,765
+270
+0.8% +$22.8K 0.13% 54
2020
Q4 		$3.24M Sell
35,495
-955
-3% -$79.2K 0.14% 59
2020
Q3 		$2.91M Buy
36,450
+16,190
+80% +$1.26M 0.15% 56
2020
Q2 		$1.4M Sell
20,260
-380
-2% -$27K 0.08% 79
2020
Q1 		$1.3M Sell
20,640
-509,394
-96% -$36.7M 0.11% 66
2019
Q4 		$41.2M Buy
530,034
+23,592
+5% +$1.84M 2.06% 20
2019
Q3 		$37.1M Buy
506,442
+17,301
+4% +$1.22M 2.09% 19
2019
Q2 		$30.1M Sell
489,141
-79,704
-14% -$4.82M 1.61% 28
2019
Q1 		$36.3M Sell
568,845
-24,192
-4% -$1.38M 1.98% 19
2018
Q4 		$30.3M Sell
593,037
-37,209
-6% -$1.88M 2.37% 17
2018
Q3 		$36.6M Buy
630,246
+166,494
+36% +$8.14M 1.76% 27
2018
Q2 		$22.5M Buy
463,752
+224,460
+94% +$10.5M 1.16% 38
2018
Q1 		$11.1M Buy
239,292
+228,267
+2,070% +$9.91M 0.61% 44
2017
Q4 		$414K Sell
11,025
-11,370
-51% -$417K 0.02% 182
2017
Q3 		$816K Buy
22,395
+6,000
+37% +$229K 0.04% 103
2017
Q2 		$646K Sell
16,395
-35,100
-68% -$1.28M 0.04% 110
2017
Q1 		$1.61M Sell
51,495
-226,980
-82% -$7.11M 0.1% 54
2016
Q4 		$8.7M Buy
278,475
+255,855
+1,131% +$8.29M 0.57% 39
2016
Q3 		$909K Buy
22,620
+3,750
+20% +$141K 0.06% 70
2016
Q2 		$627K Buy
18,870
+3,000
+19% +$103K 0.05% 81
2016
Q1 		$467K Sell
15,870
-5,100
-24% -$141K 0.03% 129
2015
Q4 		$552K Hold
20,970
– – 0.03% 123
2015
Q3 		$497K Hold
20,970
– – 0.04% 133
2015
Q2 		$498K Hold
20,970
– – 0.03% 176
2015
Q1 		$498K Buy
20,970
+1,710
+9% +$38.4K 0.03% 165
2014
Q4 		$409K Buy
19,260
+600
+3% +$12.1K 0.03% 208
2014
Q3 		$318K Hold
18,660
– – 0.02% 278
2014
Q2 		$267K Sell
18,660
-826,572
-98% -$11.2M 0.02% 308
2014
Q1 		$10.4M Buy
845,232
+28,788
+4% +$332K 0.69% 51
2013
Q4 		$8.95M Sell
816,444
-191,532
-19% -$2.16M 0.56% 54
2013
Q3 		$11.7M Sell
1,007,976
-18,444
-2% -$216K 0.83% 46
2013
Q2 		$11.5M Buy
+1,026,420
New +$12.1M 1.01% 36

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R.H. Bluestein & Co's EW Position: Q3 2022 in Review

R.H. Bluestein & Co increased its Edwards Lifesciences (EW) stake by 0.43% in Q3 2022, buying an estimated $84.7K and bringing the position to 204,527 shares worth $16.9M. The position accounts for 1.05% of the portfolio, ranked #28.

R.H. Bluestein & Co first reported a position in EW in Q2 2013 and has held it in 38 quarters since. The position peaked at $41.2M in Q4 2019. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.

  • R.H. Bluestein & Co held 204,527 shares of Edwards Lifesciences worth $16.9M as of Q3 2022.
  • R.H. Bluestein & Co bought 880 Edwards Lifesciences shares in Q3 2022, an estimated $84.7K.
  • Edwards Lifesciences made up 1.05% of R.H. Bluestein & Co's portfolio in Q3 2022, its #28 holding.
  • R.H. Bluestein & Co first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 38 quarters since.
  • R.H. Bluestein & Co's Edwards Lifesciences position peaked at $41.2M in Q4 2019.
  • 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.